logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) for urinary incontinence

< Back

Clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) for urinary incontinence

Drugs

Renal Disease and Urology

June 2021


Clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) is currently in clinical development for urinary incontinence in adults with neurogenic detrusor overactivity (NDO), as a result of spinal cord injury or multiple sclerosis (MS). Damage to the spinal cord, via MS or injuries, can disrupt communication between the spinal cord and bladder causing NDO. NDO increases pressure in the bladder and decreases the volume of urine the bladder can hold, leading to unexpected and frequent urine leakage (urinary incontinence).
Clostridium botulinum type A toxin-haemagglutinin complex is an injectable drug made from the bacteria that causes botulism. It can block the transmission between nerves and muscles causing a reduction in muscle activity and potentially aid the overactive muscles in the bladder that cause urinary incontinence. If licenced, clostridium botulinum type A toxin-haemagglutinin complex would provide a treatment option for adult patients with urinary incontinence from NDO, as a result of spinal cord injury or MS.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts